Phase II study results of HOB-294 (transdermal oxybutynin hydrochloride) for treatment of overactive bladder

The Company's Official Page[PDF]
http://www.hisamitsu.co.jp/english/pdf/HOB_E_090806.pdf
Back To Previous Page


August 6, 2009
Phase II study results of HOB-294 (transdermal oxybutynin hydrochloride)for
treatment of overactive bladder
In this report Hisamitsu Pharmaceutical Co. Ltd. (Hirotaka Nakatomi, President &
Chief Executive Officer) publishes the domestic phase II study results of HOB-294
(transdermal oxybutynin hydrochloride) under development for treatment of overactive
bladder.

HOB-294 is a transdermal product containing oxybutynin hydrochloride intended for

Latest News: Pharmaceuticals

    この内容でのリリース掲載はまだ無いか、集計されておりません。

    この内容でのリリース掲載はまだ無いか、集計されておりません。

Most Popular: Pharmaceuticals

1. Notice Regarding Worldwide Patent and Kn...
Mitsubishi Tanabe Pharma Corporation 2015/09/17
2. Announcement of FY2015 2nd Quarter Finan...
Mitsubishi Tanabe Pharma Corporation 2015/10/30
3. Mitsubishi Tanabe Pharma Enhances Operat...
Mitsubishi Tanabe Pharma Corporation 2016/02/23
4. Notice of Dividend of Retained Earnings
Mitsubishi Tanabe Pharma Corporation 2016/05/11
5. Approval of REMICADE for I.V. Infusion 1...
Mitsubishi Tanabe Pharma Corporation 2016/05/13

Latest News: Hisamitsu Pharmaceutical Co., Inc.


Most Popular: Hisamitsu Pharmaceutical Co., Inc.

1. Notice concerning acquisition result and...
2009/12/11

Categories

Go to Page Top

View: Smartphone | PC

Language: English | Japanese

Home

Terms & Conditions

TwitterFacebook

About Us